Gunhild Mari MÃ¦landsmo

List of Publications by Year
in descending order

78 papers	3,629 citations	257450 24 h-index	138484 58 g-index
81 all docs	81 docs citations	81 times ranked	8153 citing authors

#	Article	IF	Citations
1	Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer Discovery, 2014, 4, 998-1013.	9.4	1,341
2	Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature Reviews Cancer, 2017, 17, 254-268.	28.4	527
3	B7â€H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasisâ€associated genes. International Journal of Cancer, 2012, 130, 2282-2290.	5.1	128
4	Molecular profiling and characterization of luminalâ€like and basalâ€like in vivo breast cancer xenograft models. Molecular Oncology, 2009, 3, 469-482.	4.6	96
5	Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer, 2010, 10, 433.	2.6	93
6	Zebrafish as a model system for characterization of nanoparticles against cancer. Nanoscale, 2016, 8, 862-877.	5.6	74
7	Aldehyde Dehydrogenase (ALDH) Activity Does Not Select for Cells with Enhanced Aggressive Properties in Malignant Melanoma. PLoS ONE, 2010, 5, e10731.	2.5	73
8	Metabolic reprogramming supports the invasive phenotype in malignant melanoma. Cancer Letters, 2015, 366, 71-83.	7.2	70
9	<scp>STAMP</scp>2 increases oxidative stress and is critical forÂprostate cancer. EMBO Molecular Medicine, 2015, 7, 315-331.	6.9	52
10	Metastasis-associated protein S100A4 induces a network of inflammatory cytokines that activate stromal cells to acquire pro-tumorigenic properties. Cancer Letters, 2014, 344, 28-39.	7.2	46
11	Metabolic re-wiring of isogenic breast epithelial cell lines following epithelial to mesenchymal transition. Cancer Letters, 2017, 396, 117-129.	7.2	45
12	Drug-Loaded Photosensitizer-Chitosan Nanoparticles for Combinatorial Chemo- and Photodynamic-Therapy of Cancer. Biomacromolecules, 2020, 21, 1489-1498.	5.4	45
13	A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth. Cancer Immunology, Immunotherapy, 2010, 59, 1665-1674.	4.2	44
14	Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer. Breast Cancer Research, 2013, 15, R16.	5.0	42
15	Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer. Breast Cancer Research, 2019, 21, 61.	5.0	42
16	Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model. Breast Cancer Research, 2019, 21, 9.	5.0	40
17	Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft. Journal of Controlled Release, 2019, 293, 183-192.	9.9	38
18	Synthesis, characterization, and cellular uptake of magnetic nanocarriers for cancer drug delivery. Journal of Colloid and Interface Science, 2014, 433, 76-85.	9.4	31

#	Article	IF	Citations
19	Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model. BMC Cancer, 2016, 16, 191.	2.6	30
20	Basalâ€like breast cancer engages tumorâ€supportive macrophages via secreted factors induced by extracellular S100A4. Molecular Oncology, 2018, 12, 1540-1558.	4.6	30
21	Inhibition of PTP1B disrupts cellâ€“cell adhesion and induces anoikis in breast epithelial cells. Cell Death and Disease, 2017, 8, e2769-e2769.	6.3	29
22	p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance. Scientific Reports, 2019, 9, 5839.	3.3	28
23	In vivo MRI and histopathological assessment of tumor microenvironment in luminalâ€like and basalâ€like breast cancer xenografts. Journal of Magnetic Resonance Imaging, 2012, 35, 1098-1107.	3.4	27
24	Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease. BMC Cancer, 2018, 18, 739.	2.6	27
25	Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. Oncotarget, 2016, 7, 19997-20015.	1.8	25
26	Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer. Breast Cancer Research and Treatment, 2017, 162, 127-137.	2.5	24
27	Soluble AXL as a marker of disease progression and survival in melanoma. PLoS ONE, 2020, 15, e0227187.	2.5	24
28	Use of a murine secreted alkaline phosphatase as a non-immunogenic reporter gene in mice. Journal of Gene Medicine, 2005, 7, 307-315.	2.8	23
29	Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response. Breast Cancer: Targets and Therapy, 2017, Volume 9, 185-198.	1.8	23
30	Mechanism of cellular uptake and cytotoxicity of paclitaxel loaded lipid nanocapsules in breast cancer cells. International Journal of Pharmaceutics, 2021, 597, 120217.	5.2	23
31	Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases. Oncotarget, 2017, 8, 76290-76304.	1.8	23
32	Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells. Pigment Cell and Melanoma Research, 2010, 23, 449-451.	3.3	22
33	The expression of the long NEAT1_2 isoform is associated with human epidermal growth factor receptor 2-positive breast cancers. Scientific Reports, 2020, 10, 1277.	3.3	22
34	Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma. Molecular Cancer Therapeutics, 2020, 19, 895-905.	4.1	21
35	Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma. PLoS ONE, 2016, 11, e0165382.	2.5	21
36	Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basalâ€and luminalâ€like breast cancer xenografts. Molecular Oncology, 2012, 6, 418-427.	4.6	19

#	Article	IF	Citations
37	Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy . International Journal of Nanomedicine, 2019, Volume 14, 6269-6285.	6.7	19
38	MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro. Scientific Reports, 2021, 11, 10893.	3.3	18
39	Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases. Clinical and Experimental Metastasis, 2017, 34, 51-62.	3.3	16
40	Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy. Molecular Therapy, 2021, 29, 1199-1213.	8.2	16
41	Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide. Oncotarget, 2017, 8, 76921-76934.	1.8	15
42	Expression and clinical significance of Wee1 in colorectal cancer. Tumor Biology, 2016, 37, 12133-12140.	1.8	14
43	AXL inhibition improves BRAF-targeted treatment in melanoma. Scientific Reports, 2022, 12, 5076.	3.3	14
44	Serum levels of inflammationâ€related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers. International Journal of Cancer, 2020, 146, 223-235.	5.1	13
45	Immune checkpoint B7â€H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer. Prostate, 2021, 81, 838-848.	2.3	13
46	Antiâ€angiogenic therapy affects the relationship between tumor vascular structure and function: A correlation study between microâ€“computed tomography angiography and dynamic contrast enhanced MRI. Magnetic Resonance in Medicine, 2017, 78, 1513-1522.	3.0	12
47	hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma. Cell Death Discovery, 2016, 2, 16081.	4.7	11
48	Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a populationâ€based series and a randomized phase III study on adjuvant chemotherapy. Cancer Medicine, 2016, 5, 1840-1849.	2.8	11
49	In Vivo ³¹P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts. Journal of Magnetic Resonance Imaging, 2015, 41, 601-609.	3.4	10
50	Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer. Diagnostic Pathology, 2016, 11, 50.	2.0	10
51	Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes. Clinical and Experimental Metastasis, 2015, 32, 755-767.	3.3	9
52	Spheroid-Derived Cells From Renal Adenocarcinoma Have Low Telomerase Activity and High Stem-Like and Invasive Characteristics. Frontiers in Oncology, 2019, 9, 1302.	2.8	9
53	Low Î²2-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism. Oncotarget, 2016, 7, 1878-1894.	1.8	9
54	Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate. ESMO Open, 2017, 2, e000158.	4.5	8

#	Article	IF	Citations
55	Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain. Cancer Immunology Research, 2019, 7, 701-706.	3.4	8
56	Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer â€“ the MetAction study. Acta OncolÃ³gica, 2020, 59, 733-740.	1.8	8
57	ALK Inhibitors in Patients With ALK Fusionâ€“Positive GI Cancers: An International Data Set and a Molecular Case Series. JCO Precision Oncology, 2022, 6, e2200015.	3.0	8
58	Dynamic 18â€‰F-FDG PET for Assessment of Tumor Physiology in Two Breast Carcinoma Xenografts. Nuclear Medicine and Molecular Imaging, 2013, 47, 173-180.	1.0	7
59	A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases. Translational Oncology, 2019, 12, 951-958.	3.7	7
60	Biodistribution of Poly(alkyl cyanoacrylate) Nanoparticles in Mice and Effect on Tumor Infiltration of Macrophages into a Patient-Derived Breast Cancer Xenograft. Nanomaterials, 2021, 11, 1140.	4.1	7
61	Fibroblast Growth Factor 2 Conjugated with Monomethyl Auristatin E Inhibits Tumor Growth in a Mouse Model. Biomacromolecules, 2021, 22, 4169-4180.	5.4	7
62	STAMP2 is required for human adipose-derived stem cell differentiation and adipocyte-facilitated prostate cancer growth in vivo. Oncotarget, 2017, 8, 91817-91827.	1.8	7
63	Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment. Cancer Letters, 2018, 439, 1-13.	7.2	6
64	Design, synthesis and biological evaluation of 6â€substituted quinolines derived from cabozantinib as câ€Met inhibitors. Archiv Der Pharmazie, 2019, 352, e1900101.	4.1	6
65	Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients. Frontiers in Oncology, 2020, 10, 590755.	2.8	6
66	EMT-Derived Alterations in Glutamine Metabolism Sensitize Mesenchymal Breast Cells to mTOR Inhibition. Molecular Cancer Research, 2021, 19, 1546-1558.	3.4	6
67	Differential In Vivo Tumorigenicity of Distinct Subpopulations from a Luminal-Like Breast Cancer Xenograft. PLoS ONE, 2014, 9, e113278.	2.5	6
68	Serglycin Is Involved in TGF-Î² Induced Epithelial-Mesenchymal Transition and Is Highly Expressed by Immune Cells in Breast Cancer Tissue. Frontiers in Oncology, 2022, 12, 868868.	2.8	6
69	Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers. JCO Precision Oncology, 2021, 5, 286-306.	3.0	5
70	Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer. Scientific Reports, 2021, 11, 6731.	3.3	5
71	Dynamic 2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts. Molecular Imaging and Biology, 2017, 19, 271-279.	2.6	4
72	Detection of phenotypeâ€specific therapeutic vulnerabilities in breast cells using a CRISPR lossâ€ofâ€function screen. Molecular Oncology, 2021, 15, 2026-2045.	4.6	3

#	Article	IF	Citations
73	Low Concordance Between T-Cell Densities in Matched Primary Tumors and Liver Metastases in Microsatellite Stable Colorectal Cancer. Frontiers in Oncology, 2021, 11, 671629.	2.8	3
74	Argininosuccinate lyase is a metabolic vulnerability in breast development and cancer. Npj Systems Biology and Applications, 2021, 7, 36.	3.0	3
75	miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy. Breast Cancer: Targets and Therapy, 2022, Volume 14, 25-39.	1.8	3
76	From autonomy to community; new perspectives on tumorigenicity and therapy resistance. Cancer Treatment Reviews, 2015, 41, 809-813.	7.7	2
77	Novel human melanoma brain metastasis models in athymic nude fox1 nu mice: Siteâ€specific metastasis patterns reflecting their clinical origin. Cancer Medicine, 2021, 10, 8604-8613.	2.8	2
78	The MetAction project: Biomarker-directed molecularly matched therapy for end-stage cancer implemented in clinical practice.. Journal of Clinical Oncology, 2017, 35, e14033-e14033.	1.6	0